Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "trial"

2292 News Found

Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
Hospitals | April 03, 2026

Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra

Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure


Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
News | April 03, 2026

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe


India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push
Biotech | April 03, 2026

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports


Nearly 40 industry groups unite to push for EU Biotech Act II
Biotech | April 03, 2026

Nearly 40 industry groups unite to push for EU Biotech Act II

A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative


EMA moves to cut animal testing with “virtual control groups” in preclinical research
Policy | April 03, 2026

EMA moves to cut animal testing with “virtual control groups” in preclinical research

The approach, which could significantly reduce the number of rats used in certain dose-range finding studies


Cardinal Health boosts production of cutting-edge cancer therapy ingredient
News | April 03, 2026

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.


BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech
Policy | April 03, 2026

BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech

Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors


FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions
News | April 02, 2026

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants


Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
News | April 02, 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio


Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
News | April 01, 2026

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions